TY - JOUR
T1 - How health technology assessment can help to address challenges in drug repurposing
T2 - a conceptual framework
AU - Abu-Zahra, Teebah
AU - Grimm, Sabine E.
AU - Scholte, Mirre
AU - Raymakers, Adam J.N.
AU - Kesselheim, Aaron S.
AU - Joore, Manuela
N1 - Funding Information:
This project is funded by the EU under grant agreement No. 101057619. The views and opinions expressed are, however, those of the authors only and do not necessarily reflect those of the EU or European Health and Digital Executive Agency (HADEA). Neither the EU nor the granting authority can be held responsible for them. This work was also partly supported by the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract No. 22.00115. A.S.K. and A.J.N.R. report funding from Arnold Ventures and the Commonwealth Fund.
Publisher Copyright:
© 2024 The Author(s)
PY - 2024/6/1
Y1 - 2024/6/1
N2 - Drug repurposing faces various challenges that can impede its success. We developed a framework outlining key challenges in drug repurposing to explore when and how health technology assessment (HTA) methods can address them. We identified 20 drug-repurposing challenges across the categories of data access, research and development, collaboration, business case, regulatory and legal challenges. Early incorporation of HTA methods, including literature review, empirical research, stakeholder consultation, health economic evaluation and uncertainty assessment, can help to address these challenges. HTA methods can assess the value proposition of repurposed drugs, inform further research and ultimately help to bring cost-effective repurposed drugs to patients.
AB - Drug repurposing faces various challenges that can impede its success. We developed a framework outlining key challenges in drug repurposing to explore when and how health technology assessment (HTA) methods can address them. We identified 20 drug-repurposing challenges across the categories of data access, research and development, collaboration, business case, regulatory and legal challenges. Early incorporation of HTA methods, including literature review, empirical research, stakeholder consultation, health economic evaluation and uncertainty assessment, can help to address these challenges. HTA methods can assess the value proposition of repurposed drugs, inform further research and ultimately help to bring cost-effective repurposed drugs to patients.
KW - Challenges in drug repurposing
KW - Drug repurposing
KW - health technology assessment (HTA)
KW - HTA methods
U2 - 10.1016/j.drudis.2024.104008
DO - 10.1016/j.drudis.2024.104008
M3 - (Systematic) Review article
SN - 1359-6446
VL - 29
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 6
M1 - 104008
ER -